Addendum

Belzutifan (renal cell carcinoma) – Addendum to Project A25-45

Status
Status: Commission completed
Project no.
A25-107
Last updated

Report documents

  1. Addendum

    Belzutifan (renal cell carcinoma) – Addendum to Project A25-45

    published on
    Document type
    PDF document, 315 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-107_en

Dossier assessment

Indication:

Adult patients with advanced clear cell renal cell carcinoma that has progressed following 2 or more lines of therapy that included a PD‑(L)1 inhibitor and at least 2 vascular endothelial growth factor‑targeted therapies

Result of dossier assessment:
  • Patients < 65 years of age for whom everolimus is a suitable individualized treatment: unchanged after addendum: hint of a minor added benefit
  • Patients ≥ 65 years of age for whom everolimus is a suitable individualized treatment: unchanged after addendum: hint of a considerable added benefit
  • Patients for whom everolimus is not a suitable individualized treatment: unchanged after addendum: added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2025-09-18 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A25-107
Commission
Commission awarded on 12.08.2025 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent relevant page on the extent of the added benefit concludes the early benefit assessment.

DOI

https://doi.org/10.60584/A25-107_en

Connected Projects

  1. Dossier assessment

    Belzutifan (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-45
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form